Rock Creek Pharmaceuticals Announces Presentation Of Four Anatabine Projects At Neuroscience 2014

Rock Creek Pharmaceuticals, Inc.

, a drug development company focused on chronic inflammatory disease and neurologic disorders, announced today that abstracts outlining four separate preclinical studies evaluating anatabine, the primary constituent in the Company's lead investigational compound anatabine citrate, have been accepted for poster and nano symposium presentations at the upcoming annual meeting of the Society for Neuroscience, taking place November 15-19 in Washington, DC. This meeting is the premier event in the field, typically attracting approximately 30,000 attendees, with 15,000 scientific presentations and nearly 600 presenting companies. The studies were independently conducted by the Roskamp Institute, a not-for-profit research organization devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The studies were funded by either the Roskamp Foundation or by awards through the Congressionally Directed Medical Research Program. Michael J. Mullan, MBBS (MD), PhD, Rock Creek Pharmaceuticals' Chairman and CEO, commented, "The data from the accepted abstracts demonstrates the continued application of anatabine for beneficial effects in preclinical mouse models of human diseases." A list of the abstracts and timing of the presentations is provided below: Presentation title: Beneficial effects of anatabine in a mouse model of tauopathy Program #/Poster#: 40.07/D32 First Presenting Author: Daniel Paris, Ph.D., Roskamp Institute, Sarasota, Florida Presentation Time: Saturday, November 15, 3:00 PM Presentation title: Effects of anatabine on Alzheimer's disease (AD) like pathology, neuroinflammation and behavior in transgenic mouse model of AD Program #/Poster#: 307.17/D63 First Presenting Author: Megha Verma, Ph.D, Roskamp Institute, Sarasota, Florida Presentation Time: Monday, November 17, 8:00 AM Presentation title: Anatabine ameliorates cognitive impairment and neuropathological deficits in a mouse model of Gulf War Illness Program #/Poster#: 423.07/Z2 First Presenting Author: Ghania Ait-Ghezala, Ph.D., Roskamp Institute, Sarasota, Florida Presentation Time: Monday, November 17, 1:00 PM Presentation title: Delayed treatment of Anatabine after repetitive mild TBI normalizes spatial memory impairment Program #/Poster#: 486.92 First Presenting Author: Scott Ferguson, Ph.D., Roskamp Institute, Sarasota, Florida Presentation Time: Tuesday, November 18 at 8:15 AM: Nano Symposium